Deals

With Pfizer Deal, Allergan Looks Ahead: Could B+L Be In Its Sights? - Eye on Innovation

Without Pfizer Deal, Allergan Looks Ahead: Could B+L be in its Sights?

By Rich Kirkner | April 6, 2016

Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is…

Read More
OIS - Eye on Five

Eye on Five – March Edition

By Rich Kirkner | March 31, 2016

Regeneron, Bayer Join to Develop Combined Therapy Regeneron Pharmaceuticals and Bayer announced an agreement to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody…

Read More
Alcon Makes Big

Alcon Makes Big Move in MIGS

By OIS Contributor | February 23, 2016

With Transcend, Alcon Gains a Foothold in Glaucoma Device Market Contributed by Larry Haimovitch and Richard Mark Kirkner With its move to acquire Transcend Medical…

Read More
Putting Brakes on IPO, Apellis Lines Up Private Funding - Eye on Innovation

Apellis IPO Road Show Takes Different Route

By Rich Kirkner | February 16, 2016

Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the…

Read More
Close-Up Look at Progress in Surgical Presbyopia Correction - OIS News

Close-Up Look at Progress in Surgical Presbyopia Correction

By Michael Lachman | February 10, 2016

Presbyopia, the age-related loss of accommodation and near/reading vision, typically begins at about age 40 and affects nearly everyone over age 50. This huge opportunity…

Read More
Glaucoma Getting a Wake-Up Call

Glaucoma Getting a Wake-Up Call

By Larry Haimovitch | February 3, 2016

SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out…

Read More

Saunders Promises ‘Greater Impact’ on Ophthalmology

By Rich Kirkner | November 24, 2015

With the planned combination of Pfizer and Allergan to create the world’s largest pharmaceutical company, Brent Saunders, a key player in two significant acquisitions of…

Read More
Is Auris Still Building a Robot for Cataract Surgery?

Is Auris Still Building a Robot for Cataract Surgery?

By Rich Kirkner | October 1, 2015

Auris Surgical Robotics Inc., a Bay Area medical technology company that had been developing a robotic platform for cataract surgery, just raised $150 million, but…

Read More
Aquesys’ CEO Details Allergan’s Successful Bid

Aquesys’ CEO Details Allergan’s Successful Bid

By Tom Salemi | September 11, 2015

Last week’s sale of Aquesys represented a homecoming for CEO Ron Bache, who started his surgical device career at Allergan in the late 1990s. However,…

Read More
Revenue Report Card for Recent IPO Class

Revenue Report Card for Recent IPO Class

By Tom Salemi | August 28, 2015

As a rule, medical device companies have to demonstrate some level of commercial viability if they’re going to go public. A few are able to…

Read More
Q&A with Shire’s Robert Dempsey

Q&A with Shire’s Robert Dempsey

By Tom Salemi | August 6, 2015

Shire this week announced plans to acquire Foresight Biotherapeutics for $300 million. Robert Dempsey, Shire’s vice president and head of the company’s ophthalmic unit, kindly…

Read More
Is pSivida on the verge of megastar status?

Is pSivida on the verge of megastar status?

By Michelle Dalton | July 30, 2015

With three of the four sustained-release drug delivery products commercially available in the U.S. and Europe, pSivida just might prove Wall Street pundits correct and…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.